Clinical Trials
13 trialsNCT04626024 2026-05-04
TOKIN
Baylor College of Medicine
Phase 2 Active not recruiting
NCT03831776 2025-06-08
BosuPeg
St. Olavs Hospital
Phase 2 Completed
NCT04793399 2024-03-19
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Phase 1/2 Terminated
NCT02311998 2023-07-17
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02269267 2023-03-03
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Phase 2 Completed
NCT02810990 2023-02-03
BEST
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT03885830 2023-01-11
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT04655391 2022-06-09
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Withdrawn
NCT02782403 2020-11-19
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02638467 2020-11-05
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
University of Milano Bicocca
Phase 2 Completed
NCT02906696 2020-05-11
Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03205267 2017-07-02
BODO
University of Bonn
Phase 2 Unknown